Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 27, 2025FARAPOINT PFA Catheter delivers effective, safe and consistent ablation for right atrial flutter
PARIS, France, 27 November, 2025 – Boston Scientific Corporation (NYSE: BSX) today announced it has received CE mark for the FARAPOINT™ Pulsed Field Ablation (PFA) Catheter, the newest PFA...
-
Sep 18, 2025Conduction system pacing technique may promote greater ventricular synchrony and reduce long-term risk of heart failure associated with traditional right ventricular pacing
PARIS, France, 18 September 2025 – Boston Scientific Corporation (NYSE: BSX) has received CE mark approval to expand the indication for its current-generation INGEVITY™+ Pacing Leads – thin...
-
Jul 24, 2025CE MDR approval for basivertebral nerve ablation therapy designed to provide long-lasting relief from single procedure
HEMEL HEMPSTEAD, United Kingdom, 24 July, 2025 — Boston Scientific Corporation (NYSE: BSX) today announced CE mark and first procedure in Europe with the Intracept Intraosseous Nerve Ablation...
-
Jul 10, 2025Positive guidance for the Boston Scientific FARAPULSE™ Pulsed Field Ablation System marks expansion of minimally invasive treatment options for growing number of atrial fibrillation patients in the UK.
HEMEL HEMPSTEAD, United Kingdom, 10 July 2025 – Boston Scientific Corporation (NYSE: BSX) today welcomed guidance1 supporting the use of pulsed field ablation (PFA) for the treatment of atrial...
-
Jul 10, 2025Una evaluación positiva para el sistema de ablación por campo pulsado FARAPULSE™ amplía las opciones de tratamiento mínimamente invasivas para un número creciente de pacientes con fibrilación auricular
HEMEL HEMPSTEAD, Reino Unido, 10 de julio de 2025 – Boston Scientific Corporation (NYSE: BSX) celebra hoy la publicación de la guía¹ del Instituto Nacional para la Excelencia en Salud y...
-
Mar 3, 2025
Acquisition to expand Interventional Cardiology Therapies offerings with ultrasound-based renal denervation therapy for treatment of hypertension MARLBOROUGH, Mass., March 3, 2025 /PRNewswire/ --...
-
Feb 17, 2025Il catetere di ablazione FARAWAVE™ NAV e il modulo FARAVIEW™, combinati con il sistema di mappatura di Boston Scientific, consentono una cartografia durante l'ablazione per elettroporazione.
MILANO, Italia, 17 febbraio 2025 – Boston Scientific Corporation (NYSE: BSX) ha annunciato oggi di aver ottenuto il marchio CE per il catetere di ablazione FARAWAVE™ NAV, una tecnologia di...
-
Feb 17, 2025El catéter de ablación FARAWAVE™ NAV y el software FARAVIEW™, combinados con el sistema de mapeo de Boston Scientific, permiten una cartografía durante la ablación por electroporación.
MADRID, España 17 de febrero de 2025 – Boston Scientific Corporation (NYSE: BSX) anunció hoy que ha obtenido el marcado CE para el catéter de ablación FARAWAVE™ NAV, una tecnología de...
-
Feb 17, 2025FARAWAVE™ NAV Ablationskatheter und FARAVIEW™ Software in Kombination mit dem Boston Scientific Mapping-System ermöglichen Mapping für die Pulsed Field Ablation
DÜSSELDORF, Deutschland - 17. Februar 2025 – Die Boston Scientific Corporation (NYSE: BSX) hat die CE-Kennzeichnung für den navigationsfähigen FARAWAVE™ NAV-Ablationskatheter zur Behandlung...
-
Feb 17, 2025FARAWAVE™ NAV Ablation Catheter and FARAVIEW™ Software combine with Boston Scientific mapping system to provide mapping during pulsed field ablation
LONDON, United Kingdom, 17 February, 2025 – Boston Scientific Corporation (NYSE: BSX) today announced it has received CE mark for the navigation-enabled FARAWAVE™ NAV Ablation Catheter for the...
-
Jan 16, 2025
First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed...
Nov 16, 2024Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation MARLBOROUGH, Mass. and...
-
Nov 15, 2024
Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a medical technology company focused on the development and...
-
Oct 24, 2024Diagnostic algorithm shown to detect early signs of worsening heart failure and reduce hospitalisations for patients with cardiac implantable electronic devices
HEMEL HEMPSTEAD, United Kingdom, 24 October, 2024 – Boston Scientific (NYSE: BSX) announced that the National Institute for Health and Care Excellence (NICE), which provides evidence-based...
-
Sep 9, 2024Un sondaggio dimostra che depressione e stanchezza sono comuni tra le persone che vivono con il dolore cronico
MILANO, Italia, 9 Settembre 2024 – Il mese di settembre è dedicato alla sensibilizzazione sul dolore cronico, una condizione che colpisce più di 10 milioni di persone in Italia1. Boston...
-
Sep 9, 2024Befragung zeigt, dass junge Menschen in Folge chronischer Schmerzen mit Depressionen und Angstzuständen zu kämpfen haben.
Düsseldorf, Deutschland – 09. September 2024 – Eine neue Umfrage unter Menschen mit chronischen Schmerzen in Deutschland zeigt die teils deutlichen Auswirkungen chronischer Schmerzen auf die...
-
Sep 9, 2024Responses of 1,000 people with chronic pain in the UK reveal the far-reaching burden of chronic pain on mental health, with many feeling misunderstood
HEMEL HEMPSTEAD, United Kingdom – 9 September, 2024 – A new survey highlights the profound impact chronic pain has on the lives of people living in the UK, often severely affecting their...
Aug 27, 2024Boston Scientific Corporation (NYSE: BSX) today announced it has obtained CE mark for the ACURATE Prime™ Aortic Valve System, the newest transcatheter aortic valve replacement (TAVR) technology...
Jun 20, 2024Vercise™ Neural Navigator 5 con tecnologia STIMVIEW™ XT è progettato per semplificare la procedura per le persone affette da patologie neurologiche.HEMEL HEMPSTEAD, Regno Unito – Giovedì 20 giugno 2024 – Boston Scientific Corporation (NYSE: BSX) ha ottenuto il marchio CE per il software Vercise™ Neural Navigator 5 con tecnologia...
Jun 20, 2024Vercise™ Neural Navigator 5 con tecnología STIMVIEW™ XT está diseñado para agilizar el procedimiento para las personas que viven con afecciones neurológicasMadrid, 20 de junio de 2024 – Boston Scientific Corporation (NYSE: BSX) ha obtenido la aprobación del marcado CE para su Software Vercise™ Neural Navigator 5 con tecnología STIMVIEW™ XT....
- Jun 20, 2024Vercise™ Neural Navigator 5 mit STIMVIEW™ XT-Technologie soll das Verfahren für Menschen mit neurologischen Störungen vereinfachen
DÜSSELDORF – 20. Juni 2024 – Die Boston Scientific Corporation (NYSE: BSX) hat die CE-Kennzeichnung für die Vercise™ Neural Navigator 5 Software mit STIMVIEW™ XT Technologie erhalten,...
- Jun 20, 2024Vercise™ Neural Navigator 5 with STIMVIEW™ XT technology is designed to streamline procedure for people living with neurological conditions
HEMEL HEMPSTEAD, United Kingdom – 20 June 2024 – Boston Scientific Corporation (NYSE: BSX) has obtained CE Mark on the Vercise™ Neural Navigator 5 Software with STIMVIEW™ XT technology,...
-
Jan 8, 2024Acquisition to expand urology portfolio with differentiated technologies to treat urinary and bowel dysfunction
Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Axonics, Inc. (Nasdaq: AXNX), a publicly traded medical technology company primarily...
Dec 12, 2023El nuevo acuerdo de compra de energía virtual (VPPA, por sus siglas en inglés) contribuye a alcanzar las ambiciones de descarbonización de la compañía en su camino hacia cero emisionesMADRID, ESPAÑA, 12 de diciembre de 2023 – Boston Scientific Corporation (NYSE: BSX) ha activado su primer acuerdo europeo de compra de energía virtual (Virtual Power Purchasing Agreement en inglés) junto a BayWa r.e., empresa alemana líder en el desarrollo de energía renovable y proveedora de soluciones que impulsará a la compañía a cumplir sus objetivos de descarbonización.
- Dec 12, 2023New virtual power purchase agreement helps to advance the company’s decarbonisation goals on its path to net zero
MADRID, SPAIN, 12 December 2023 – Boston Scientific Corporation (NYSE: BSX) has activated its first European virtual power purchase agreement (VPPA) with leading renewable energy developer and solutions provider BayWa r.e., helping the company make progress on its decarbonisation targets.